Search

Displaying results 2711 - 2720 of 9132 in total
  1. Drug

    TT 173

    go.drugbank.com/drugs/DB17717
    Investigational

    TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental

  2. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. … AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  3. Drug

    Mitotane

    go.drugbank.com/drugs/DB00648
    ApprovedInvestigational

    Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and

  4. Drug

    Altropane

    go.drugbank.com/drugs/DB04947
    Investigational

    Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and

  5. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing. … PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes.

  6. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246703] As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC. … [A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes.

  7. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  8. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. … [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728]

  9. Drug

    Pentaglobin

    go.drugbank.com/drugs/DB15865
    Investigational

    Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. … [A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]

  10. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.